ArticleNPJ precision oncology2025
Early detection of urological tumors based on genomic characteristics of cell-free DNA fragments: a multi-center study.
Article in NPJ precision oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- A cfDNA fragmentomics classifier for noninvasive differentiation of benign and malignant renal masses.Molecular biomedicine · 2026Article
- Plasmonic Nanoarray Biosensors for Non-Invasive Cancer Diagnostics.Biosensors · 2026Review
- Dynamic Precision Oncology for Real-Time Molecular Monitoring and Management in Urothelial Carcinoma.International journal of molecular sciences · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Cell-free DNA (cfDNA) has shown potential in distinguishing cancer patients from healthy individuals. This study investigates cfDNA fragmentomics-fragmentation patterns, end motifs (EDMs), and breakpoint motifs (BPMs)-to develop an early detection method for bladder urothelial carcinoma (BLCA), prostate adenocarcinoma (PRAD), and clear cell renal cell carcinoma (ccRCC). Using low-coverage whole genome sequencing (lcWGS) on plasma samples from 758 participants (including BLCA, PRAD, ccRCC, benign prostatic hyperplasia patients, and healthy controls), we analyzed cfDNA features. Machine learning models (logistic regression, support vector machine, random forest, XGBoost, Stacking) distinguished urological tumors from non-tumor cases with AUCs of 96% (BLCA), 99% (ccRCC), 92% (PRAD), and 89% (pan-cancer). Key discriminators included 6-bp EDMs and BPMs. A proposed two-tier screening strategy combining pan-cancer and cancer-specific features offers a cost-effective, non-invasive approach for early detection with strong clinical potential.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.